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ABSTRACT
Tumor-associated antigens (TAAs) have been the
most activelyemployed targets in the clinical diagno-
sisandtreatmentofhumancarcinoma,suchasPSAin
the diagnosis of prostate cancer and NY-ESO-1 in the
20 immunotherapy of melanoma and other cancers.
However, identification of TAAs has often been ham-
pered by the complicated and laborsome laboratory
procedures. In order to accelerate the process of
tumor antigen discovery, and thereby improve diag-
25 nosis and treatment of human carcinoma, we have
made an effort to establish a publicly available
HumanPotentialTumorAssociatedAntigendatabase
(HPtaa) with potential TAAs identified by in silico
computing (http://www.hptaa.org). Tumor specificity
30 was chosen as the core of tumor antigen evaluation,
together with other relevant clues. Various platforms
of gene expression, including microarray, expressed
sequence tag and SAGE data, were processed and
integrated by several penalty algorithms. A total of
35 3518 potential TAAs have been included in the data-
base, which is freely available to academic users. As
far as we know, this database is the first one address-
ing human potential TAAs, and the first one integrat-
ing various kinds of expression platforms for one
40 purpose.
INTRODUCTION
Tumor-associated antigens (TAAs) have been the most
actively employed targets in the clinical diagnosis and treat-
ment of human carcinoma. TAAs are encoded by normal or
45 mutated genes in the human genome whose products can elicit
humoral or cellular anti-tumor immunity. They can be clas-
siﬁed as tissue restrictive and non-tissue restrictive antigens,
according to their expression pattern in normal tissues (NTs).
Tissue restrictive TAAs, including cancer-testis antigens (CT
50 antigens),differentiationantigensandoncofetalantigens,have
deeply affected the clinical oncology. For example, PSA as a
differentiation antigen is indispensable in diagnosis and prog-
nosis evaluation of prostate cancer (1), AFP as an oncofetal
antigen hasbeen widely used inthe diagnosis of hepatocellular
55 carcinoma (2), and NY-ESO-1 as a cancer-testis antigen has
been shown to induce broad integrated immune responses in
melanoma patients (3). As a result, identiﬁcation of clinical
applicable TAAs is of great importance to cancer immunolo-
gists and clinicians.
60 Traditionally, TAAs are identiﬁed through T cell epitope
cloning, serological analysis of cDNA expression libraries,
subtraction hybridization and differential display analysis (4).
Laboratory procedures, although successful, are extremely
laborious. Recently, immunoinformatics has emerged as an
65 efﬁcient way for the identiﬁcation of TAAs. These in silico
methods were generally based on the fact that tumor-speciﬁc
expression patterns usually reﬂect heterogeneity of the gene
products, which, given that protein expression correlates with
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doi:10.1093/nar/gkj082mRNA expression, is at the core of immunogenicity. Thus,
successful identiﬁcation of novel TAAs through expression
database mining has not been reported occasionally (5–8).
It has been conventionally considered that different expres-
5sion platforms cannot be integrated together because of the
difﬁculties of normalization. Based on the fact that individual
series of expression data can be used separately in the case
of tumor antigen identiﬁcation, we believe that all kinds of
expression platforms can be integrated by gathering all
10 the individual results. Our own experience shows that
platform integration greatly increases the efﬁciency of TAA
identiﬁcation.
In order to accelerate the process of tumor antigen discov-
ery, and thus improve diagnosis and treatment of human car-
15 cinoma, we decided to establish a publicly available database
for potential TAAs (pTAA) identiﬁed by in silico computing,
named Human Potential Tumor Associated Antigen database
(HPtaa). As mentioned above, tumor-speciﬁc expression pat-
tern not only correlates with immunogenicity, but also is the
20 prerequisite for clinical application. Thus, we chose tumor-
speciﬁc expression as the core of tumor antigen evaluation.
Other relevant clues were also considered; including coding
capacity, chromosomal location, subcellular location and the
knowledge of gene function. As far as we know, this database
25 is the ﬁrst one addressing human potential TAAs, and the ﬁrst
one integrating various kinds of expression platforms for one
purpose.
DATABASE CONSTRUCTION
Data source
30 The HPtaa database integrates various expression platforms,
including carefully chosen publicly available microarray
expression data, GEO SAGE data, expressed sequence tag
(EST) expression data together with other relevant databases
required for TAA discovery, such as CGAP (9), CCDS
35 (http://www.ncbi.nlm.nih.gov/projects/CCDS/), OMIM (10),
Uniprot (11) and the Gene Ontology database (12).Microarray
datasets were divided into normal tissue series and cancer
series. Normal tissue series include ﬁve famous datasets:
GNF (13,14), UCLA (http://microarray.genetics.ucla.edu/
40 geneexp/public/), GENENOTE (15), GeMDBJ (https://
www.gemdbj.jp/dgdb/) and GEOJP (http://www.genome.
rcast.u-tokyo.ac.jp/normal/). The cancer series include 45
datasets from 12 series, covering 14 major cancer types
(16–27). The EST (28) and SAGE data (29) covers 9 addi-
45 tional cancer types, resulting in HPtaa covering a total of
23 cancer types.
Data processing
Each microarray dataset was processed individually to avoid
the problem of normalization. For datasets of NTs, we used
50 knowncancer-testisantigens(30)asa training set togeneratea
detection call matrix, and then tissue restriction score (TRS)
was computed for each probe. The tissue restriction threshold
for each dataset was determined according to the TRS interval
containing 90% CT antigens, and then the TRS of all the
55 normal tissue datasets were assembled by Unigene ID. The
tissue restriction penalty (TRP) was computed according to all
the probes’ TRS of each Unigene and their conﬁdence evi-
denced by source sequences of probes and the amount of
samples in the corresponding dataset. See Supplementary
60 Data for details of the algorithms.
Differential expression analysis and signiﬁcance tests were
carried out separately for each cancer microarray datasets and
each cancer type of the EST and SAGE expression data. For
each signiﬁcantly expressed probe, the cancer/normal ratio
65 was computed and assembled by Unigene ID. An overexpres-
sion penalty (OP) for each cancer type was computed accord-
ing to the overexpression ratios and their conﬁdence accessed
by source sequences of probes. The tumor speciﬁcity penalty
(TSP) was then computed as TSP ¼ TRP · OP. This algo-
70 rithm is designed according to the assumption that tumor
speciﬁcity increases in proportion to OP and TRP. (Figure 1).
Database content
All genes with TSP > 115 were considered as tumor speciﬁc
and were includedin the HPtaa database.Thiscutoff was set to
75 obtain an optimal balance between database content and iden-
tiﬁcation of known tumor antigens. The CGAP, GO, CCDS,
UniProt and OMIM databases were thereafter integrated to
annotate each pTAA, and all the original expression data
were picturized and linked to the corresponding pTAAs.
80 Statistics
The HPtaa database contains 3518 potential TAAs for up to 23
human cancer types. To test the quality of the database, we
checked how many known tumor antigens it contains. We
found that 41 known CT antigens (50% of all known CT
85 antigens) (30), 6 known differentiation antigens (33% of all
known differentiation antigens) (31) and 2 known oncofetal
antigens (100%, CEA and AFP) were successfully screened
out (see Supplementary Data for detailed information). Inter-
estingly, most of the CT antigens screened out with current
90 algorithms generally have a high overexpression rate com-
pared with those not found. This shows that with our statistical
signiﬁcance test, genes stably upregulated in cancerous tissues
are more likely to be picked out, which are also more valuable
than those occasionally overexpressed. Totally 3163 known
95 genes and 355 uncharacterized genes were included in the
database, among which 1804 genes have publication reports,
2172 genes have CCDS annotation. The database contains 237
membrane proteins, 172 secretory proteins and 127 genes
mapped to the X chromosome. (See Data Retrieval below
100 for the signiﬁcance of these properties.)
DATA RETRIEVAL
The database provides an easy-to-use query interface. Users
can query interesting genes against HPtaa with a basic search,
or query for pTAAs with deﬁned features through an advanced
105 search. The cancer type choice allows users to choose pTAAs
of their cancer types of interest. Chromosome choice allows
users to choose whether the pTAAs should locate on the X or
on the Y chromosome, where CT antigens aggregate. The
coding capacity choice allows users to deﬁne the coding
110 capacity of a pTAA, as coding genes are more likely to be
TAAs. It should be noted that novel genes often have unde-
termined coding capacity. Subcellular location choice allows
D608 Nucleic Acids Research, 2006, Vol. 34, Database issueusers to choose membrane pTAAs or secretory pTAAs.
Membrane proteins are more valuable in the clinical treatment
of carcinoma, while secretory proteins are of more interest to
diagnostics. The mRNA choice allows users to choose pTAA
5with an mRNA sequence, which is easy to identify. OMIM
choice allows users to choose whether pTAAs have publica-
tion supported functional annotations. Genes with no OMIM
ID usually have no cancer-related reports. ‘ESTs from NT’
choice allows users to choose the number of ESTs from non-
10 germinal and non-fetal NTs clustered to each pTAA.
The result page of a database search contains three impor-
tant parameters for evaluating a pTAA, i.e. the TRP, OP and
TSP, as outlined above. When trying to identify highly tumor-
speciﬁc genes, the three values should be considered together.
15 TRP deﬁnes the degree of restrictive expression of a given
gene across human NTs and its conﬁdence. The higher the
TRP, the more restrictive is the expression of a given gene
across NTs. OP deﬁnes whether the expression of a given gene
is signiﬁcantly upregulated in cancerous tissues compared
20 with corresponding NTs. The value of OP does not merely
reﬂect the differential expression ratio, but combines the ratio
with other clues indicating overexpression. The higher the OP
value, the higher is the likelihood of overexpression. TSP
gives an overall view of the tumor speciﬁcity. The higher
25 the TSP, the higher is the degree of tumor-speciﬁc expression.
Users will ﬁnd that for a given pTAA/gene the OP and TSP
values varies between different cancer types. The reason
behind this is that individual researchers will usually need
tumor-speciﬁc genes that are overexpressed in the particular
30 cancer type they study. Cancer type speciﬁc OP and TSP
values may accommodate for this requirement.
DISCUSSION
How to make your choice
The HPtaa database aims directly at clinical diagnosis and
35 treatment of human carcinoma, and users should thus choose
pTAAs according to their purpose. If a user wants to ﬁnd
tumor markers for the cancer types he/she studies, the secret-
ory pTAAs with the highest cancer type speciﬁc TSP and OP
values should be favored irrespective of the TRP value. The
40 rationality of this lies in the fact that tumor markers usually
have less tissue-restrictive expression, and the expression in
cancerous tissue needs to be extremely high to favor about
detection. We recommend users to examine the ﬁgure of dif-
ferential expression ratio to evaluate the details and degree of
45 overexpression (Figure 2).
If users want to ﬁnd pTAAs with therapeutic value, the
pTAAs with highest TRP should be selected, as higher TRP
values are likely to imply lesser side effects. We recommend
users to examine in detail the ﬁgure of normal tissue expres-
50 sion in the detail page, as pTAA with extremely low detection
value across NTs may best serve the therapeutic purposes. By
Figure 1. The flow chart of data procession of HPtaa database.
Nucleic Acids Research, 2006, Vol. 34, Database issue D609Figure 2. Mean differential expression ratio of PSA across various cancer types. When upregulated significantly in cancerous tissues, the value was computed as
‘cancer/normal’; when downregulated significantly the value was computed as ‘– (normal/cancer)’. The y-axis shows the names of the cancer datasets and source
sequences of the probes in a given dataset. Red color represents upregulation and blue color downregulation.
D610 Nucleic Acids Research, 2006, Vol. 34, Database issuerestricting the number of ESTs from NT, users can further
screen out tissue-restrictive genes also evidenced by EST
data. With respect to subcellular location, membrane
pTAAs are best targets for monoclonal antibody treatment,
5while intracellular pTAAs constitute a good repertoire of
peptide vaccination targets.
Evaluating potential TAA
The expression patterns of CT antigens were usually evaluated
by endpoint RT–PCR. As RT–PCR is generally more sensitive
10 than other methods, tissue restrictive genes in the database
may appear less tissue restrictive when analyzed by RT–
PCR with 35 cycles. In our experience, the coincidence of
HPtaa deﬁned tumor speciﬁcity with RT–PCR result should
be  10%. As a result, we recommend real-time PCR or north-
15 ern blot instead of end point PCR in evaluating the expression
difference between cancerous tissues and NTs of human body.
Functional considerations
As more and more TAAs have been found to be related to
carcinogenesis, the functional aspects of tumor antigens have
20 gradually aroused immunologists’ attention. As pTAAs are
virtually tumor-speciﬁc genes, together with the fact that
many organ-speciﬁc genes are found to be related to the func-
tion of the organs they are speciﬁcally expressed, it is not
surprising to ﬁnd that these genes also contribute to the pro-
25 liferation or metastasis of human carcinomas. In evidence of
this, users can ﬁnd many genes known to be related to car-
cinogenesis in our database. To help with users interested in
functional aspects of cancer-speciﬁc genes, we provide an
annotation of gene ontology and motif for each gene in the
30 detail page.
Users may ﬁnd that some genes with high-TSP are actually
immune system-speciﬁc genes. We suspect that the upregu-
lation of these genes may originate from tumor inﬁltration
activity of immune cells. However, as it has been shown
35 that tumor cells overexpress genes encoding antibodies with
unknown speciﬁcity (32), we cannot exclude the possibility
that other unrecognized mechanisms may explain the high-
TSP scores of these genes.
FUTURE DIRECTION
40 The development of penalty algorithms for the HPtaa database
has been guided by practical experience. Further experimental
validation will be carried out to evaluate their efﬁcacy, and to
facilitate reﬁning of the algorithms. As large-scale expression
data accumulate fast, more expression data will be integrated
45 to improve gene and cancer type coverage. A classiﬁcation
system will be established to address the expression privilege
of pTAAs in NTs, as in the case of tumor antigens.
Citing HPtaa
Users are requested to cite this article and quote the HPtaa
50 home page URL (http://www.hptaa.org).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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